NCT04088604View on ClinicalTrials.gov

Irinotecan Hydrochloride Liposome Injection (LY01610) For Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

February 15, 2019

Primary Completion Date

December 17, 2021

Study Completion Date

December 17, 2021

Conditions
Advanced Solid Tumor
Interventions
DRUG

LY01610 ( Irinotecan hydrochloride liposome injection )

Part1-Dose Escalation and Part1-Dose Extension : subjects take LY01610;

DRUG

LY01610 ( Irinotecan hydrochloride liposome injection ) with 5-Fu（Fluorouracil Injection）

Part2-Dose Escalation and Part2-Dose Extension : subjects take LY01610 with 5-Fu;

DRUG

Irinotecan Hydrochloride Injection（CAMPTO®）

Irinotecan Hydrochloride Injection（CAMPTO®） pharmacokinetics comparative study

Trial Locations (1)

100021

Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

All Listed Sponsors
lead

Luye Pharma Group Ltd.

INDUSTRY

NCT04088604 - Irinotecan Hydrochloride Liposome Injection (LY01610) For Advanced Solid Tumors | Biotech Hunter | Biotech Hunter